NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in advanced cancers: phase I trial

Immune checkpoint inhibitors (ICIs) have led to improved treatment outcomes…" />

We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.